MTOR and urinary bladder cancer: A recent genome-scale clustered regularly interspaced short palindromic repeats (CRISPR)-dCas9 activation screen in bladder cancer cells showed that CDK4/6 inhibitors bind effectively to a variety of compounds targeting PI3K, AKT, mTOR, FGFR1/2, MEK1/2, VEGFR1/2/3, PDGFRb, cKIT, and even pan-CDK inhibitors [32].